Compare IPAR & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPAR | TWST |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 1995 | 2018 |
| Metric | IPAR | TWST |
|---|---|---|
| Price | $95.96 | $67.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $116.60 | $46.88 |
| AVG Volume (30 Days) | 206.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | 2.34 | ★ 63.89 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $1,317,700,000.00 | $376,572,000.00 |
| Revenue This Year | $3.86 | $18.91 |
| Revenue Next Year | $7.89 | $15.07 |
| P/E Ratio | $71.58 | ★ N/A |
| Revenue Growth | ★ 21.26 | 20.32 |
| 52 Week Low | $77.21 | $23.30 |
| 52 Week High | $142.50 | $69.20 |
| Indicator | IPAR | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 66.47 |
| Support Level | $92.30 | $41.85 |
| Resistance Level | $98.64 | N/A |
| Average True Range (ATR) | 2.97 | 4.26 |
| MACD | 0.87 | 1.45 |
| Stochastic Oscillator | 89.54 | 85.46 |
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.